Lung cancer signature

a lung cancer and signature technology, applied in the field of compositions and methods of cancer diagnosis, research and therapy, can solve the problem of not being able to identify which specific patients are at high risk of relaps

Inactive Publication Date: 2015-06-04
RGT UNIV OF MICHIGAN
View PDF2 Cites 22 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0008]The present disclosure relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present disclosure relates to cancer markers and panels of cancer markers as diagnostic markers and clinical targets for lung cancer. In some embodiments, the present invention provides compositions, kits, systems and methods for determining the likelihood of survival of a subject based on altered expression of one or more cancer markers.

Problems solved by technology

While it is known that 35-50% of patients with stage I disease will relapse within five years (Williams et al., Thorac. Cardiovasc. Surg. 82:70 ; Pairolero et al., Ann. Thorac. Surg. 38:331 ), it is not currently possible to identify which specific patients are at high risk of relapse.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lung cancer signature
  • Lung cancer signature
  • Lung cancer signature

Examples

Experimental program
Comparison scheme
Effect test

example 1

Methods

[0092]Cell culture: The A549 human lung adenocarcinoma cell line was obtained from the American type Culture Collection (Manassas, Va.) and maintained in RPMI-1640 medium with glutamine, supplemented with 10% FBS, penicillin, and streptomycin and tested for mycoplasma contamination. All tissue culture media and media supplements were purchased from Life Technologies (Gaithersburg, Md.). The porcine transforming growth factor beta 1 (TGF-β) was purchased from PeproTech (Rocky Hill, N.J.). In all experiments cells at 40-50% confluency were serum starved for 24 h and treated with TGF-β (5 ng / ml) for 72 h. At the end conditioned media collected was centrifuged at 2000 g for 20 minutes and filtered through 0.2 μm filter to remove the intact cells and debris and stored at −80 0 C until further processing. Cells in the culture dishes were lysed in RIPA buffer and processed for western immunoblotting for assessing the expression of epithelial and mesenchymal markers. Protein concentr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
volumeaaaaaaaaaa
volumeaaaaaaaaaa
volumeaaaaaaaaaa
Login to view more

Abstract

The present disclosure relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present disclosure relates to cancer markers as diagnostic markers and clinical targets for lung cancer.

Description

[0001]The present application claims priority to U.S. Provisional Patent Application Ser. No. 61 / 904,711, filed Nov. 15, 2013, the disclosure of which is herein incorporated by reference in its entirety.FIELD OF THE INVENTION[0002]The present disclosure relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present disclosure relates to cancer markers as diagnostic markers and clinical targets for lung cancer.BACKGROUND OF THE INVENTION[0003]Lung cancer remains the leading cause of cancer death in industrialized countries. About 75 percent of lung cancer cases are categorized as non-small cell lung cancer (e.g., adenocarcinomas), and the other 25 percent are small cell lung cancer. Lung cancers are characterized in to several stages, based on the spread of the disease. In stage I cancer, the tumor is only in the lung and surrounded by normal tissue. In stage II cancer, cancer has spread to near...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): G01N33/574C12Q1/68
CPCG01N33/57423C12Q1/6886G01N2800/52C12Q2600/118C12Q2600/106C12Q2600/158
Inventor KESHAMOUNI, VENKATESHWAR G.OMENN, GILBERT S.CHEN, GUOANBEER, DAVID G.STANDIFORD, THEODORE J.
Owner RGT UNIV OF MICHIGAN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap